Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1725985
PUBLISHER: GlobalData | PRODUCT CODE: 1725985
Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025
PUBLISHED:
PAGES: 302 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
GlobalData's clinical trial report, "Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025" provides an overview of Duchenne Muscular Dystrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Product Code: GDHC7227CTIDB
Table of Contents
Table of Contents
List of Tables
List of Figures
- Report Guidance
- GlobalData Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Duchenne Muscular Dystrophy
- Mar 31, 2025: Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
- Mar 27, 2025: Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
- Mar 19, 2025: Precision Biosciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of DMD at the 2025 MDA
- Mar 19, 2025: FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
- Mar 19, 2025: Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Mar 17, 2025: Roche to Share Latest Scientific Advancements From Its Neuromuscular Portfolio at Muscular Dystrophy Association 2025 Conference
- Mar 17, 2025: ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
- Mar 17, 2025: Capricor Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- Mar 10, 2025: PepGen Announces Presentation on PGNEDODM-1 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Mar 10, 2025: PepGen Announces Presentation on PGNEDO-51 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Mar 04, 2025: Pepgen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients With DMD
- Feb 24, 2025: Precision Biosciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
- Feb 24, 2025: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
- Feb 21, 2025: Scholar Rock To Present Additional Clinical Data From the Phase 3 Sapphire Trial at the 2025 MDA Clinical & Scientific Conference
- Feb 18, 2025: Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Feb 12, 2025: Percheron Makes Rapid Progress in Partnering Discussions; Initial Proposals Expected to Be Submitted in February 2025
- Feb 11, 2025: Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247
- Feb 05, 2025: Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
- Jan 29, 2025: PepGen Announces CONNECT Program Updates
- Jan 28, 2025: Roche reports positive topline outcomes from DMD treatment trial
- Clinical Trial Profile Snapshots
Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About GlobalData
- Contact Us
- Source
Product Code: GDHC7227CTIDB
List of Table
List of Tables
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figure
List of Figures
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- GlobalData Methodology
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.